OraSure Technologies Supports Rapid HCV Testing Initiatives Across the U.S. in Recognition of National Hepatitis Testing Day
May 19 2015 - 9:15AM
OraSure Technologies, Inc. (Nasdaq:OSUR), a leader in point of care
diagnostic tests and specimen collection devices, today announced
its support of numerous rapid hepatitis C (HCV) testing events for
National Hepatitis Testing Day, taking place on May 19, 2015. These
testing initiatives, happening across the country, will help
encourage thousands of people across the U.S. to get tested for
hepatitis C with the OraQuick® HCV rapid test.
National Hepatitis Testing Day is an educational initiative of
the U.S. Centers for Disease Control and Prevention's (CDC)
Division of Viral Hepatitis and the U.S. Department of Health and
Human Services. The observance reminds people at risk for hepatitis
to be tested, and encourages healthcare providers to educate
patients about chronic viral hepatitis and testing.
The CDC estimates that 5.2 million Americans have been exposed
to or are infected with HCV, including 1 in 30 baby boomers (those
born between 1945 and 1965). HCV is the most common chronic
blood-borne infection in the U.S., and a leading cause of chronic
liver disease, cirrhosis and liver cancer. It is estimated that up
to 75 percent of those individuals with HCV are unaware of their
infection.
Nasdaq MarketSite Opening Bell and Hepatitis C Testing
Panel
OraSure will preside over the opening of the Nasdaq Stock Market
today, May 19th in recognition of National Hepatitis Testing Day.
Joining OraSure will be the Chronic Liver Disease Foundation
(CLDF), members of New York City Council, and healthcare
professionals and community advocates. A live webcast of the NASDAQ
Opening Bell will be available at:
http://www.nasdaq.com/about/marketsitetowervideo.asx.
Following the market opening ceremony, CLDF will be hosting a
panel discussion featuring healthcare practitioners and leading
public health officials who are implementing comprehensive HCV
screening initiatives in a variety of clinical and non-clinical
settings. The panel, "Fighting the HCV Epidemic: Best Practices in
Rapid HCV Testing and Linkage to Care," will take place from 10:00
AM to 11:30 AM, and will be webcast live. To watch the webcast live
or to view an archived version, please visit:
http://www.chronicliverdisease.org/special_event/NATIONAL_HEP_TESTING_DAY/
New Rapid HCV Testing Initiative in
Pharmacies
The CLDF announced today that it will collaborate with Walgreens
to offer free HCV testing with the OraQuick® HCV Rapid Test at
select Walgreens retail pharmacy locations in major cities
throughout the country.
National Hepatitis Testing Day Events
OraSure is supporting numerous HCV testing events, using the
OraQuick® HCV rapid test, taking place across the country in 25
states and in major cities including New York, Chicago, Atlanta,
Denver, Seattle, Phoenix and Washington, D.C. In New York City,
community-based healthcare organization BOOM!Health is offering
testing through its mobile van stationed in Times Square today in
recognition of National Hepatitis Testing Day. A full listing of
testing events can be found at
https://npin.cdc.gov/htd/EventList.aspx
About the OraQuick® HCV Rapid
Test
OraQuick® HCV is the first and only FDA-approved and CLIA-waived
point of care test for detection of HCV infection in at-risk
individuals. The simple platform enables healthcare providers to
deliver a diagnosis based on lab-accurate test results in 20
minutes, using venipuncture or fingerstick blood.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture
and distribution of point of care diagnostic and collection devices
and other technologies designed to detect or diagnose critical
medical conditions. Its first-to-market, innovative products
include rapid tests for the detection of antibodies to HIV and HCV
on the OraQuick® platform, oral fluid sample collection,
stabilization and preparation products for molecular diagnostic
applications, and oral fluid laboratory tests for detecting various
drugs of abuse. OraSure's portfolio of products is sold globally to
various clinical laboratories, hospitals, clinics, community-based
organizations and other public health organizations, research and
academic institutions, distributors, government agencies,
physicians' offices, commercial and industrial entities and
consumers. The Company's products enable healthcare providers to
deliver critical information to patients, empowering them to make
decisions to improve and protect their health.
CONTACT: Media Contact:
Jennifer Moritz
Zer0 to 5ive for OraSure Technologies
917-748-4006
jmoritz@0to5.com
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Sep 2023 to Sep 2024